Abstract 323P
Background
An immune checkpoint inhibitor that targets programmed cell death protein 1 (PD-1) or programmed death ligand 1 (PD-L1) has recently been discovered, and it demonstrates superior treatment efficacy and improves prognosis over existing chemotherapeutic agents in non-small cell lung cancer. Several studies have demonstrated correlations between computed tomography (CT) imaging features and PD-L1 expression in lung adenocarcinoma (ADC). However, there have been few studies on the association between lung squamous cell carcinoma (SCC) and CT findings. Thus, we aimed to identify the associations between CT findings and PD-L1 expression in SCC and to develop models to predict the expression of PD-L1 in lung SCC using CT.
Methods
This retrospective study included 99 patients diagnosed with SCC and pretreatment CT images and PD-L1 expression assay results. We performed CT feature analysis of the tumors using pretreatment CT images. We then constructed multiple logistic regression models to predict PD-L1 positivity in the total patient group and in 41 advanced-stage (≥ stage IIIB) patients. To identify predictive efficiency, areas under the receiver operating characteristic curves (AUCs) of each model were calculated.
Results
Among the 99 patients, 68 (68.7%) were PD-L1-positive and among the 41 advanced patients, 30 (73.2%) were PD-L1-positive. For the total patient group, the AUC of the ‘total significant features model’ (tumor stage, primary tumor size, pleural nodularity and lung metastasis) was 0.637, and that of the ‘selected feature model’ (pleural nodularity) was 0.556. For advanced-stage patients, the AUC of the selected feature model (primary tumor size, central distribution, pleural nodularity, and pulmonary oligometastases) was 0.882. Among these factors, the presence of pleural nodularity and pulmonary oligometastases had high odds ratios (4.11 and 9.60, respectively).
Conclusions
Our model was able to predict PD-L1 expression in patients with advanced-stage SCC of the lung, and the presence of pleural nodularity and pulmonary oligometastases were notable predictive CT features of PD-L1. A predictive model based on CT features may facilitate non-invasive assessment of PD-L1 expression.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
This study was supported by a VHS Medical Center Research Grant, Republic of Korea (grant number: VHSMC 21007).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
364P - Tepotinib with an EGFR-tyrosine kinase inhibitor (TKI) in patients with EGFR-mutant MET-amplified NSCLC: A case series
Presenter: Azura Ahmad
Session: Poster viewing 05.
365P - Patterns of progression on first-line osimertinib in patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): A Swiss cohort study
Presenter: Alexandra Schuler
Session: Poster viewing 05.
366P - EGFR amplification is a putative resistance mechanism for NSCLC-LM patients with TKI therapy and is associated with poor outcome
Presenter: Hainan Yang
Session: Poster viewing 05.
367P - High-dose aumolertinib in EGFR-mutant NSCLC patients with brain metastases: Primary data from ACHIEVE
Presenter: Yun Fan
Session: Poster viewing 05.
368P - A special Imaging pattern of bilateral diffuse metastases in advanced lung adenocarcinoma harboring EGFR mutations was associated with a favorable prognosis to EGFR-TKIs
Presenter: Zhen-Bang Gu
Session: Poster viewing 05.
370P - Outcomes in patients with EGFR-mutant locally advanced or metastatic NSCLC co-mutations receiving aumolertinib as first-line treatment: A retrospective study
Presenter: Fang Cun
Session: Poster viewing 05.
371P - Real-world data of first-line treatment with aumolertinib for elderly EGFR+ NSCLC patients
Presenter: Haitao Zhang
Session: Poster viewing 05.
373P - Safety and efficacy of aumolertinib treatment in patients with advanced NSCLC harboring uncommon EGFR mutations: Cohort 2
Presenter: WenFeng Fang
Session: Poster viewing 05.